ConductScience.org, home

Comparison · NCT03640312-1a0c4e1d

QUARTET LDQT vs Candesartan: Rate of Adverse Events of Special Interest

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. QUARTET LDQT vs Candesartan: Rate of Adverse Events of Special Interest. Trial comparisons, record NCT03640312-1a0c4e1d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03640312-1a0c4e1d

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.50.3360.664wilson
Risk in group 20.3330.1920.512wilson
Risk difference, group 1 minus group 20.167-0.07580.383newcombe hybrid score
Risk ratio, group 1 over group 21.50.8122.77log
Odds ratio, group 1 over group 220.7165.59log
Number needed to treat, for one more participant with the outcome on QUARTET LDQT than on Candesartan6from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1QUARTET LDQT
Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.~QUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.
1632OG000
Group 2CandesartanPatients randomized to the comparison arm took a once daily 8mg candesartan.~Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.1030OG001

Outcome

Type
OTHER_PRE_SPECIFIED
Title
Rate of Adverse Events of Special Interest
Description
Rate of pre-specified adverse events that are known side effects of active ingredients at the participant level.
Time frame
12 weeks
Population

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
NCT number
NCT03640312
Phases
PHASE2
Conditions
Hypertension
Interventions
QUARTET LDQT, Candesartan
Lead sponsor
Washington University School of Medicine
Results first posted
2023-09-22

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03640312-1a0c4e1d